Lundbeck Q3 2019 Financial Results
Both studies in brexpiprazole pivotal programme in PTSD commenced
Post-traumatic Stress Disorder (PTSD)
*
~8.6m U.S. adults affected, but -80% estimated to be undiagnosed
*
Growing economic and social burden of care
* Inadequate response with approved SSRIs - polypharmacy the norm
Study
objective¹)
To evaluate the efficacy, safety, and tolerability of 12-week brexpiprazole + sertraline combination
treatment in adult subjects with PTSD (n = ~600)
Two studies in the pivotal programme (phase III):
* Brexpiprazole (fixed dose (2, 3mg) and flexible dose up to 3mg) in combination with sertraline
*
*
Primary endpoint: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
U.S. dedicated study
1) Clinicaltrials.gov ID: NCT04124614. The second study not listed yet
25
Lundbeck
⭑View entire presentation